PTC Therapeutics (PTCT) closed FY 2025 with Q4 revenue of US$164.7 million and a basic EPS loss of US$1.67, alongside net income excluding extra items of a US$135.0 million loss, setting a mixed tone for the year. Over the past six quarters, revenue has ranged from US$196.8 million in Q3 2024 to US$1.2 billion in Q1 2025, while basic EPS has swung from an 11.09 gain in Q1 2025 to losses such as US$1.39 in Q3 2024. This gives investors a wide set of margins to weigh. With the company now showing profitability on a trailing twelve month basis yet still reporting quarterly losses, the latest results highlight the question of how sustainable those margins are.

See our full analysis for PTC Therapeutics.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the dominant stories about PTC Therapeutics and which parts of the narrative the latest margins support or challenge.

Twelve month profit built on one huge Q1

• On a trailing twelve month basis, PTC reported US$1.7b in revenue and US$682.6 million in net income, but Q1 2025 alone contributed US$1.2b of revenue and US$866.6 million of net income, far above the other five quarters that sit between US$164.7 million and US$213.2 million of revenue and losses or modest profit.
• Bulls argue that this recent move into profitability, plus a reported 37.1% trailing five year earnings growth rate, supports the idea of a stronger underlying earnings engine. However, the heavy reliance on a single outsized quarter and the mention of high non cash earnings create tension with that bullish story.
  • Supporters point to products like Sephience and a broader rare disease portfolio as drivers for sustained earnings, while the mixed quarterly pattern, including a US$135.0 million loss in Q4 2025, shows that profitability has not been consistent across the period.
  • The bullish view that profit margins can stay attractive sits alongside data showing negative shareholders’ equity and a high non cash component to earnings, which many investors treat as reasons to question how durable those margins really are.

Some investors who buy into the positive long term story will want to see how that case is laid out in detail before deciding how much weight to give this one very strong year of results. 🐂 PTC Therapeutics Bull Case

Recent quarters swing between profit and loss

• Within FY 2025 alone, revenue moved from US$1.2b in Q1 to US$211.0 million, US$178.9 million and US$164.7 million in Q2 to Q4, while basic EPS shifted from a US$11.09 gain in Q1 to losses of US$0.83 and US$1.67 in Q2 and Q4 and only a small US$0.20 gain in Q3.
• Bears highlight this pattern as evidence that the business is still vulnerable, arguing that reliance on a narrow product set and regulatory outcomes, along with forecasts for an average 8.9% yearly decline in earnings and modest 3.3% yearly revenue growth over the next three years, limits confidence that the strong trailing period can be repeated.
  • This cautious view lines up with concerns about elevated debt, recent insider selling and negative shareholders’ equity, which all show up in the risk summary alongside the swings between quarterly profit and loss.
  • At the same time, the fact that Q3 2025 delivered US$15.9 million of net income on US$211.0 million of revenue, sandwiched between two loss making quarters, shows the business can generate profit in shorter windows, which some readers may see as a partial counterpoint to the most pessimistic expectations.

Readers who are focusing on the more cautious arguments will often want to test how well these concerns line up with the detailed bear case before leaning too heavily on the recent profit swing. 🐻 PTC Therapeutics Bear Case

Cheap P/E and big DCF gap put valuation in focus

• The stock last traded at US$64.49, which on the supplied figures equates to a P/E of 7.8x versus peers at 28.1x and the US biotech industry at 17.8x, and it is also shown as sitting well below a DCF fair value of US$178.64 and an analyst consensus price target of US$88.07.
• Consensus narrative points out that this apparent discount comes alongside forecasts for shrinking margins and a move from current 39.4% margins to 9.3% over three years, so investors weighing the low P/E and large DCF gap against slower forecast growth and ongoing risks such as negative equity and high non cash earnings are essentially deciding how much of that gap they think can realistically close.
  • The reported forecast that earnings could reach US$134.6 million by about 2029, down from the trailing US$682.6 million, helps explain why some remain cautious even though the current price sits below both the DCF fair value and the consensus target.
  • At the same time, the fact that the stock is described as cheaper on P/E than both peers and the wider biotech group reinforces why valuation keeps coming up as a central talking point whenever these earnings and forecasts are reviewed together.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for PTC Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With that mix of optimism and concern in mind, do not wait on others to form the full picture for you. Review the underlying figures and judge how the potential risks and rewards stack up by weighing the 3 key rewards and 5 important warning signs

See What Else Is Out There

PTC Therapeutics mixes one very strong quarter with several loss making periods, alongside negative shareholders’ equity and high non cash earnings that raise durability questions.

If that jumpy earnings profile and balance sheet risk make you uneasy, compare it with companies screened for stronger financial footing through the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.